Cystic Fibrosis and Health Information
Ph: +61 3 9076 2315
Cystic Fibrosis research
In close association with his Alfred based clinical practice with cystic fibrosis (CF) patients, Professor Wilson has active research programs investigating:
- Gene-potentiating therapy in CF
- Use of telemedicine to improve outcomes in CF
- Prediction of natural history from physiological monitoring
- Enhanced nutrition, anti-reflux therapy, and nocturnal hypoxia in CF outcomes
- Quality improvement through the use of electronic health records
The increased use of videoconferencing (telemedicine) means that patients who either live in communities remote from major health providers or are housebound, can consult face-to-face with their medical practitioners, viewing their medical records and images securely and as rapidly as pulling out a file and opening it.
Professor Wilson is part of a consortium called the Monash Alliance, comprising Monash University faculties and affiliated hospitals, the Division of General Practice, government departments, and various research and health delivery organisations. The Monash Alliance is developing the technology and information systems for telemedicine. This will enable medical practitioners to consult directly with remote based patients, and with health care workers for particular situations. The eHealth project has received funding from the Department of Health, Victoria, and the Commonwealth Department of Broadband, Communications and the Digital Economy. The Cystic Fibrosis Telehealth Service is now part of Alfred Health’s telemedicine group, planned to be launched in 2017.
Further information on telehealth and how it works.
The CF Service has conducted a number of clinical trials on CF gene potentiators and correctors that significantly improve activity of the defective gene product causing this disease. Collaborative studies have identified how the CFTR gene regulates cell metabolism in health and disease.